Is Novo Nordisk (NVO) the Best ADR Stock to Buy According to Hedge Funds?
We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...
GLP-1 drugmaker bemoans copycats
Pharma giant Novo Nordisk, which makes the obesity drug Wegovy, says the widespread availability of copycat medications is hurting its sales.
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
NBC Los Angeles21h
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.
BioSpace21h
Novo’s Obesity Pipeline Keeps Evolving With up to $1B Lexicon Deal
Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...
Novo Nordisk inks licensing pact with Lexicon for obesity candidate
Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...
BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag
Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...
STAT23h
Novo Nordisk sets sights on new type of oral obesity drug
Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...